China Approves First Homegrown 9-Valent HPV Vaccine.
China has approved its first domestically developed 9-valent HPV vaccine, Xinkening®9. The vaccine was jointly developed by Xiamen University, the Xiang An Biomedicine Laboratory led by Dr. Ning-shao Xia, and Wantai BioPharm.
This marks a breakthrough. Xinkening®9 is the second 9-valent HPV vaccine in the world, and the first from outside the U.S.. It ends more than a decade of foreign monopoly in this field.
Unlike current vaccines made by yeast-based systems, Xinkening®9 utilizes a new Chinese technology platform. It relies on E. coli to produce virus-like particles, reducing costs and avoiding foreign patents.
HPV (human papillomavirus) causes nearly all cervical cancer cases. The 9-valent vaccine protects against nine types of HPV, including the most dangerous strains. It also helps prevent other genital cancers and warts in both women and men.
The need is urgent. China has over 300 million women aged 9–45, but 70%–80 % have not received the HPV vaccine. Barriers include high costs and limited access to imports.
Now, with a homegrown option, access may improve. The new vaccine could boost supply, lower prices, and expand coverage, especially in underserved areas.
In short, this approval is a scientific milestone and a public health victory. China now can independently produce and supply a world-class HPV vaccine—and protect millions from preventable cancers.
Additional reporting by CCTV.
If you liked this article, why not read: Men in Multiple Chinese Cities Receive Imported 9-Valent HPV Vaccine
